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Abstract. The muscle regulatory protein myogenin ac-
cumulates in differentiating muscle cells when the cul-
ture medium is depleted for serum. To investigate the
regulation of myogenin gene expression, we have iso-
lated and characterized the Myf4 gene which encodes
the human homologue of murine myogenin. Serum
components, basic FGF (b-FGF), transforming growth
factor R (TGF-a), and EGF, agents which suppress
differentiation of muscle cells in vitro, down-regulate
the activity of the Myf4 gene, suggesting that it con-
stitutes a nuclear target for the negative control ex-
erted by these factors. The 5' upstream region contain-
ing the Myf4 promoter confers activity to a CAT
reporter plasmid in C2C12 myotubes but not in fibro-
blasts and undifferentiated myoblasts. Unidirectional
5' deletions of the promoter sequence reveal that rv200
nucleotides upstream of the transcriptional start site
are sufficient for cell type-specific expression. The
I
N vertebrate organisms skeletal muscle cells develop
from multipotential mesodermal stem cells. Following
commitment to the myogenic lineage, the cells form the
myotomal compartment which gives rise to body muscula-
ture. Myogenic differentiation in vivo and in vitro is charac-
terized by the synthesis of muscle-specific structural pro-
teins. A family of myogenic regulatory factors has recently
been identified and was suggested to play a crucial role in
myogenic lineage determination and during the acquisition
of the differentiated muscle phenotype. MyoD, the prototype
of positive regulators in muscle development, was cloned
from 5-azacytidine converted C3H mouse 10Tl/2 myoblasts
(Davis et al., 1987) and subsequently from human (Braun
et al., 1989a) and chicken (Lin et al., 1989), designated as
Myf3 and cMD1, respectively. Myogenin, another muscle
regulatory protein was identified in rat (Wright et al ., 1989)
and mouse myogenic cell lines (Edmondson and Olson,
1989), and in humanmuscle tissue where it was called Myf4
(Braun et al., 1989a). Two other cDNAs encoding the struc-
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forced expression of the muscle determining factors,
MyoDI, Myf5, and Myf6 and to a lesser degree
Myf4, results in the transactivation of the Myf4 pro-
moter in C3H mouse 10Tl/2 fibroblasts. Pathways po-
tentially involved in conveying signals from the cell-
surface receptors to the Myf4 gene were probed with
pertussis- and cholera toxin, forskolin, and CAMP. Di-
butyryl-cAMP and compounds that stimulate adenylate
cyclase inhibit the endogenous Myf4 gene and the
Myf4 promoter in CAT and LacZ reporter constructs.
Conversely, pertussis toxin which modifies Gi protein
stimulates Myf4 gene expression. In summary, our
data provide evidence that the muscle-specific expres-
sion of the Myf4 gene is subject to negative control by
serum components, growth factors and a cAMP-depen-
dent intracellular mechanism. Positive control is ex-
erted by a pertussis toxin-sensitive pathway that pre-
sumably involves G proteins.
turally related proteins Myf5 and Myf6 were also isolated
from human skeletal muscle (Braun et al., 1989a, 1990).
The homologues of Myf6, MRF4 and herculin have been
identified in rat (Rhodes and Konieczny,, 1989) and mouse
(Miner and Wold, 1990), respectively. Each of the four
known myogenic factor cDNAs when expressed in 10TI/2
fibroblasts or in other nonmuscle cells is sufficient to convert
these cells to myoblasts, which under appropriate growth
conditions withdraw from the cell cycle and differentiate into
myotubes. A similar myogenic activity has also been re-
ported for the human myd gene which has not been charac-
terized at the molecular level to date (Pinney et al., 1988) .
Given the muscle determining capacity of these factors, it
is evident that the regulation oftheir genesconstitutes an im-
portant level of control in myogenesis. Expression of Myf
genes in vivo is restricted to skeletal muscle tissue and its
embryonic precursor cells (for review see Olson, 1990; Sas-
soon et al., 1989; Ott et al., 1991; Bober et al., 1991). The
overexpression of transfected myogenic factor cDNAs in
nonmuscle tissue culture cells results in autoactivation of the
corresponding endogenous gene and the other members of
905the MyoD1 gene family (Braun et al . 1989b ; Thayer et al.,
1989) . In established muscle cell lines and during develop-
ment, however, only subsets ofthese genes, for example, ei-
ther MyoDI or Myf5 but not both, are active (Braun et al.,
1989b), indicating that the muscle determination genes are
regulated differently. In proliferating myoblasts, myogenin
fails to be expressed and its synthesis starts only at the onset
of differentiation (Wright et al., 1989 ; Edmondson and Ol-
son, 1989 ; Braun et al ., 1989b) . Together, these observa-
tions suggest that positive autoregulation, but also other
cellular factors and extrinsic signals may play a role in con-
trolling the activity of the MyoD gene family.
In proliferating myoblasts in vitro the decision to differen-
tiate depends on the removal of serum factors, usually by
replacing high concentrations ofFCS by low concentrations
ofhorse serum . Addition ofFGF or transforming growth fac-
tor (3 (TGF-,Q)l to BC3H1 mouse muscle cells in culture has
been shown to inhibit differentiation and the accumulation
of muscle-specific gene products (Clegg et al ., 1987;
Lathrop et al ., 1985 ; Massagu¬ et al ., 1986 ; Olson et al.,
1986 ; Vaidya et al . 1989) . The repression of myogenin ex-
pression in growing myoblasts and its rapid up-regulation af-
1 . Abbreviationsusedin thispaper: CAT, chloramphenicol acetyltransferase
gene ; CT, cholera toxin; HS, horse serum ; MCK, muscle creatine kinase;
PT, pertussis toxin; TGF-0, transforming growth factor beta .
The Journal of Cell Biology, Volume 115, 1991
ter the removal of serum suggests that transcription of the
myogenin (Myf4) gene and the induction of terminal differ-
entiation may be correlated .
To begin to study myogenin regulation at the molecular
level, we have isolated and sequenced the humanMyf4 gene.
Here, we present evidence that the Myf4 promoter directs
transcription only in differentiated myotubes, but not in
fibroblasts and proliferating myoblasts . The activity requires
the presence of muscle-specific regulatory helix-loop-helix
proteins, and/or factors acting downstream ofthese since the
Myf4 promoter can be transactivated in nonmuscle cells by
the expression of MyoDl, Myf5, andMyf6. High concentra-
tions ofFCS or growth factors, such as basic FGF, TGF-/3,
and EGF, suppress Myf4 expression . Similarly, compounds
that lead to high intracellular CAMP levels also exert nega-
tive control on the Myf4 gene . Stimulation ofthe Myf4 pro-
moter by a pertussis toxin (PT)-sensitive signal transduction
pathway suggests that Gi proteinmay be involved in the regu-
lation of Myf4 .
Materials andMethods
Materials
Figure 1. Organization and nucleotide
sequence of the human myogenin gene
Myf4 . (A) Partial restriction map indi-
cating sites used to generate subclones
for sequence determination . Exons are
shownbynumerals . Coding andnoncod-
ing sequences are indicated by hatched
and open bars, respectively. (B) Deter-
mination of the start site for transcrip-
tion : analysis by RNA protection . The
RNA probe was generated from a ge-
nomicfragment (DdellSstl)asdescribed
in Materials and Methods . mcs indicates
the multiple cloning site of the plasmid
pBS which is part of the transcribed
probe . Plasmid PBR 322 digested with
HaeIII was used as size marker (M) . G
and C are sequencing ladders . MR is
a RNA size marker of 185 nucleotides .
P indicates the RNA probe . Protected
RNA fragments obtained with 20 Fig
(lane 1) and 40 lAg (lane 2) of human fe-
tal limb RNA are shown . (C) Nucleo-
tide sequence and the predicted amino
acid sequence of the Myf4 gene . The
transcriptional start site is referred to as
+1 . The putative TATA box sequence
is underlined . Potential MyoD1 binding
sites are indicated by boxes.
Bovine recombinant basic FGF (bFGF) and mouse EGF were purchased
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CCCCAAAAGTGGAATCTGTTAGCTGCTCTGAGTCTTGATCCTTCTTATCCCTGGATACTGAGTGCCCATGAA
TGCCCAGAATCTGAAGCAGTCCCATTCTTTCCCAGGAAGTCTTTAAAAGAGTCTCATCGACTGATGTAGTGT
GGTTAAGGTGCTGTCAGGAAGCAAGGAGATGGATAAGTTGGCTCTTAAGGCCCCTTCCAGCCTAAGCCTACC
CTTCCTTGTTCCCTCCTCCCCCTATACCCACCAGCTTCTTCGGGACTCGAAGGAGACAGCAGGCAGGCCGCC
CAGCTAGGAGTAATTGAAAGGAGCAGA GAGGGGAATGTGTCCTCCCCCAACGCCCCTGCCCCACAGGGG
CTGCTGAGAAATGAAAACTAATCAAATTACACCCGACGGCCTCCCGACCCGTGCACAGGAGCCCGCCTGGGC
CAGGGGCAGGCTGGCAGGGTGGGGTGGGGGCCATGCGGGAGAAAGAAGGGGAATCACATCTAATCCACTGTA
AACGCCTTATGTGCAGCAACAGCTTAGAGGGCTCAGGTTTCTGTGGCGTTGGCTATATTTATCTCTGGTTCC
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ATGCCAGCGGGGAGGGMUAALGGCACCCAGCA TTG r G,GCGTGAGGGGCTGCTGGAGCTTGGGGGCTGGTGG
CAGGAACAAGCCCTTTCCGACCCCATGGAGCTGTATGAGACATCCCCCTACTTCTACCAGGAACCCCGCTTC
MetGluLeuTyrGluThrSerProTyrPheTyrGlnGluProArgPhe
TATGATGGGGAAAACTACCTGCCTGTCCACCTCCAGGGCTTCGAACCACCAGGCTACGAGCGGACGGAGCTC
TyrAspGlyGluAsnTyrLeuProValHisLeuGlnGlyPheGluProProGlyTyrGluArgThrGluLeu
ACCCTGAGCCCCGAGGCCCCAGGGCCCCTTGAGGACAAGGGGCTGGGGACCCCCGAGCACTGTCCAGGCCAG
ThrLeuSerProGluAlaProGlyProLeuGluAspLysGlyLeuGlyThrProGluHiSCYBProGlyGln
TGCCTGCCGIGGGCGTGTAAGGTGTGTAAGAGGAAGTCGGTGTCCGTGGACCGGCGGCGGGCGGCCACACTG
CyaLeuProTrpAlaCysLysValCyaLysArgLysSerValSerValAspArgArgArgAlaAlaThrLeu
AGGGAGAAGCGCAGGCTCAAGAAGGTGAATGAGGCCTTCGAGGCCCTGAAGAGAAGCACCCTGCTCAACCCC
ArgGluLysArgArgLeuLysLysValAsnGluAlaPheGluAlaLeuLysArgSerThrLeuLeuAsnPro
AACCAGCGGCTGCCCAAGGTGGAGATCCTGCGCAGTGCCATCCAGTACATCGAGCGCCTCCAGGCCCTGCTC
AsnGlnArgLeuProLYBValGluIleLeuArgSerAlaIleGlnTyrIleGluArgLeuGlnAlaLeuLeu
AGCTCCCTCAACCAGGAGGAGCGTGACCTCCGCTACCGGGGCGGGGGCGGGCCCCAGCCAGGGGTAAGTGGC
SerSerLeuAsnGlnGluGluArgAspLeuArgTyrArgGlyGlyGlyGlyProGlnProGly
CATCCCATCCCCCTGCCCCAAGGG -0 .4kb- GGACTAGGCAGAGAGAGACATCAAAGAATNGCTGTGCCC
CAGCCTTGCCTTCGCCCTGTCTTGCAGGTGCCCAGCGAATGCAGCTCTCACAGCGCCTCCTGCAGTCCAGAG
ValProSerGluCysSerSerHisSerAlaSerCyr .SerProGlu
TGGGGCAGTGCACTGGAGTTCAGCGCCAACCCAGGGGTAAGTGAGGCCTGACTGGTAACCTTGCGTCCAATC 1138
TrpGlySerAlaLeuGluPheSerAlaAsnProGly
CCTCAGTCCCTCCCTGGGCCAGGTTCTCCCCTCTr -0 .9kb- GCCTCAAGAACCCCCACTGCTCACCCAG
GTACCACCTTCCCACCTCCCCTTACAGGATCATCTGCTCACGGCTGACCCTACAGATGCCCACAACCTGCAC
AspHisLeuLeuThrAlaAspProThrAspAlaHisAsnLeuHis
TCCCTCACCTCCATCGTGGACAGCATCACAGTGGAAGATGTGTCTGTGGCCTTCCCAGATGAAACCATGCCC
SerLeuThrSerIleValAspSerIleThrValGluAspValSerValAlaPheProAspGluThrMetPro
AACTGAGATTGTCTTCCAAGCCGGGCATCCTTGCGAGCCCCCCAAGCTGGCCACAGATGCCACTACTTCTGT
Asn
AGCAGGGGCCTCCTAAGCCAGGCTGCCCTGATGCTAGGAAGCCAGCTCTGGGGTGCCATAGGCCAGACTATC
CCCTTCCTCATCCATGTAAGGTTAACCCACCCCCCAGCAAGGGACTGGACGCCCTCATTCAGCTGCCTCCTT
AGAGGAGAGGGCATCCCTTTCCAGGGAGGTAAAGCAGGGGACCAGAGCGCCCCCTCGTGTATGCCCCAGCTC
AGGGGGCAAACTCAGGAGCTTCCTTTTTATCATAACGCGGCCTCTAATTCCACCCCCCAAGTGAAACGGTTT
GAGAGACGCCGTGCCCTGACCTGGACAAGCTGTGCACGTCTCCTGTTCTGGTCTCTTCCCGATGCAGTGGCT
GGCTGGCCTGCCCTGAATTGAGAGAGAAGAAGGGGGAGAGGAACAGCCCTCTGTTCCCAAGTCCTGGGGGGC
CAAACTTTTGCAGTGAATATTGGGAACCTTCCAGTGGTTTTATGTTTTGTTTTGTTTCGTGTGTTGTTTGTA
AAGCTGCCATCCGACCAAGGTCTCCTGTGCTGAAGTTGCCGGGGACAGGCAGGGAAAAGGGGTTGGGGCCTC
T2 G000GTGATTTCTTTTGTTAACAAAGCATCGTGTGGTTTTGCCGGAATT
from Boehringer-Mannheim Biochemicals (Germany) . Human transform-
ing growth factor (hTGF-S1) was obtained from R&D Systems (England)
Cholera toxin (CT), PT, forskolin, dibutyryl CAMP, and heparin-Sepharose,
were purchased from Sigma Chemical Co. (St. Louis, MO). (I°C)-L-chlor-
amphenicol was purchased from NEN Products (Boston, MA) and 5-bromo-
4-chloro-3-indolyl-/3-D-galactopyranosid from Boehringer-Mannheim.
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Figure 1.
Isolation ofthe HumanMyf9 Gene andDetermination ofthe Nucleotide
Sequence. 1 x 106 plaques ofa human genomic DNA library constructed
in phage lambda EMBL3 (kind gift of A. M. Frischauf, MRC, London)
were screened according to Benton and Davis (1977) using the restrictionfragments ofthe human Myf4cDNA as hybridization probes which repre-
sent the 5' and the 3' end, respectively. A positive recombinant phage was
purified and analyzed with various restriction enzymes according to stan-
dard procedures (Maniatis et al ., 1982) . Subfragments were cloned into
M13 mp18 and 19 vectors and used for DNA sequencing (Sanger et al .,
1977) . In addition, unidirectional nested deletions (Henikoff, 1984) were
utilized . All presented sequence data were generated on two strands and by
repeated sequencing runs .
Determination ofthe Transcriptional Start Site. The Ddel/Ssti frag-
ment encompassing the Myf4 promoter region was subcloned into the
SmaI/Sacl sites of the vector pBS. To generate complementary RNA, the
vector was linearized by digestion with HindIII and transcription was
started from the T7 promoter in the presence of 32(P)-UTP (3,000 Ci/
mmol) . The probe was purified on a polyacrylamide gel and hybridized to
40 tcg of totalRNA from human fetal limb muscle . Hybridization was per-
formed in 10 ul of buffer containing 80% deionized formamide, 40 mM
Pipes, pH 6 .4, 400mM NaCl, 1 mM EDTA at 45°C overnight after an ini-
tial denaturation step at 85°C for 10 min . 300 Alof a digestion mix contain-
ing 0.3M sodiumacetate, pH 7.0, 5 mM EDTA, 8 14g/ml RNase A, 16 AIM]
RNase TI were added, and the reaction was incubated for 1 h at 37 °C . After
digestion with proteinase K, phenol/chloroform extraction, and ethanol
precipitation, the probe was denatured and resolved on a sequencing gel .
Construction ofMyf4PromoterDriven ReporterPlasmids. To generate
the plasmid MyAl, the 1.1-kb NcoI/NcoI fragment encompassing the 5' up-
stream region ofthe Myf4 gene up to thetranslational start codon was blunt
ended with T4 polymerase and inserted into the blunt ended HindIn site
of the 3N-polylinker CAT vector (kind gift of G . Schiitz, German Cancer
Research Center, Heidelberg, Germany) in 5'-3' orientation to obtain an in
frame fusion . The same NcoI/NcoI fragment was digested with mung bean
nuclease to remove the AUG start codon and cloned into the LacZ vector
containing a nuclear localization signal (Bonnerot et al ., 1987) to obtain
Myf4-nls LacZ . The shorter Myf4 promoter fragment NcoI/PflMl was
blunt ended and cloned into the Smal site of the plasmid 3N-polylinker
chloramphenicol acetyltransferase gene (CAT) to generate the plasmid
Myf4s . The 5'deletion clones weregenerated in theplasmidpBS bydirected
ExoUI digestion (Henikoff, 1984) or by using the restriction enzymes ApaLl
and Mbol . The resulting fragments were recloned into the CAT vector and
analyzed by nucleotide sequence determination .
Cell Culture andDNA TFansfections. Mouse C2C12 muscle cells (Yaffe
and Saxel, 1977) were obtained from the American TypeCulture Collection
(ATCC ; Rockville, MD) and grown in DMEM supplemented with 20%
FCS, 5mM glutamine, 50 U/ml ofpenicillin, and 50tcg/ml ofstreptomycin .
To induce differentiation, cells were shifted to DMEM medium containing
5% horse serum (HS) . C3H IOTI/2 fibroblastswere grown inBMEmedium
supplemented with 10% FCS . Culture media and sera were obtained from
Gibco Laboratories (Grand Island, NY) . C2C12 cells (5 x 10 5/10-cm
dish) were stably transfected with 1 kg of supercoiled pSV2-neo plasmid
and 20 kgof Myf41 plasmid orMyf4-LacZ reporterplasmid . StableC2C12
cell lines harboring the plasmids RSVCAT or/3-actin-CAT (Pl-CAT; Lohse
and Arnold, 1988) were also generated and used as constitutively express-
ing reporter control . Cotransfections were performed by the standard cal-
cium phosphate precipitation method described earlier (Braun et al .,
1989c) . G418-resistant colonies were selected in medium containing 400
jig/ml G418 (Geneticin; Gibco Laboratories) and tested for the expression
of CAT or (3-galactosidase . All expressing clones showed proper up-
regulation of either CAT or nuclear lacZ under differentiation conditions
(5% HS) . Four randomly selected clones were used in this study. Transacti-
vation of the Myf41 plasmid in IOTI/2 fibroblasts was performed by tran-
sient transfections of 10 F+g of reporter plasmid together with 10 Rg of the
expression vectors pEMBL-Myf3, pEMBL-Myf4, pEMBL-Myf5, and
pEMBL-Myf6 and 5 kg of ORSVgal expression plasmid used as internal
standard . 20 hg of Myf41 or the various 5' deletion mutants Myf4/883,
Myf4/619, Myf4/377, and Myf4/211 were transiently transfected into C2C12
cells and chick primary breast muscle cells or skin fibroblasts together with
5 tcg oftheinternalcontrolplasmidRSVsgal . CAT activity was determined
3 d lateraccording to standard procedures (German, 1985) . Media contain-
ing drugs and toxins were changed daily .
CAT Assays and Determination ofLacZ-Pbsitive Cells. CAT activity
ofstably transfected lines was measured in cell extracts normalized to pro-
teinconcentration which was determined using the BioRad-Kit . Intransient
transfections, the cotransfected RSVpgal plasmid was always used to cali-
brate the CAT assays. The conversion of chloramphenicol substrate was
quantitated by scintillation counting of the products separated on thin-layer
plates . Each CAT value represents the mean of at least three independent
experiments . LacZ (S-galactosidase) activity was determinedby cytochemi-
cal staining using 5-bromo-4-chloro-3-indolyl-S-D-galactopyranosid as
substrate .
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Figure 2. Activity of the Myf4 promoter in transiently and stably
transfected C2C12 muscle cells . (A) TransientCAT activity of the
plasmids Myf41 and Myf4s in differentiated and undifferentiated
C2C12 cells. Numbers indicate the percentage of substrate conver-
sion . The 0-actin promoter containing CAT plasmid has been de-
scribed previously (Lohse and Arnold, 1988) . Plasmid SVO-CAT
was used as negative control . Myf4-anti contains the promoter frag-
ment in antisense orientation. (B) Myf41 CAT activity in stably
transfected C2C12 clones grown in 20% FCS (lanes 1-4) and 5%
HS (lanes 5-8) for 5 d . (C) Comparison of activation pattern for
the Myf41 transgene and the endogenous creatine kinase (MCK)
gene . Specific enzyme activities were determined in duplicates as
described under Materials and Methods at the indicated times after
serum was shifted to induce differentiation . One representative re-
sult from three independent experiments is shown .
908Figure 3 5' promoter deletions of Myf4-CAT reporter constructs are active in chick primary breast muscle cells but not in fibroblasts .
The indicated plasmids were transiently transfected into primary cell cultures of 10-d chick embryos and CAT activity was determined
after transfection . The amount of cellular extracts used was standardized according to the (3-gal activity from the cotransfected RSVSgal
vector. The structure of the promoter deletion constructs is shown schematically.
Determination of Creatine Kinase and Intracellular CAMP . Specific
activity ofmuscle creatine kinase (MCK) was measured in cellular extracts
using the kit from Sigma Chemical Co. according to the procedure given
by the supplier. The concentration of CAMP was determined by RIA using
the kit from Amersham International (Amersham, UK) . Values represent
means of three independent measurements .
RNA Analysisfrom 77ssue Culture Cells. Isolation of RNA, gel elec-
trophoresis, RNA transfer, and hybridization conditions have been de-
scribed previously (Braun et al ., 1989b) . Myogenin (Myf4) mRNA has
been detected using a 700-bp probe from the fend ofthe ratcDNA (Sas-
soon et al ., 1990) labeled with ( 3ZP) dCTP by random priming . The
GAPDH probe is a 1,100-bp segment ofthe mouse glyceraldehyde phos-
phate dehydrogenase cDNA .
Results
Isolation and Structural Analysis oftheHuman
Myogenin Gene MYF-4
To isolate the MYF4 gene, anEMBL-3 phage lambda library
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of human genomic DNA was screened with Myf4-specific
cDNA probes . Several recombinant phages were purified
which hybridized to separate probes of the 5' and the 3' end
of the Myf4 cDNA . The coding information for Myf4 is lo-
cated on an internal 5-kb EcoRI restriction fragment (Fig.
1 A) . It is split into three exons, the first of which encodes
the complete NH2-terminal half of the molecule, including
the entire HLH domain . The transcriptional start site has
been determined by RNAse protection using the com-
plementary RNA transcript of an appropriate genomic DNA
fragment and RNA from human fetal limb muscle (Fig. 1
B) . According to this analysis, the mRNA starts 52 nucleo-
tides upstream of the AUG initiation codon for translation .
The nucleotide sequence encompassing all three exons, part
of the introns and 1.1-kb of 5' upstream DNA containing the
putative promoter region has been determined (Fig . 1 C) .
TheTATA-box is preceded by a secondATrich element and
several motifs for potential MyoDI binding sites . The se-
909Figure 4. Transactivation of plasmid Myf41 in 10T1/2 fibroblasts .
Transient CAT activity of the reporter plasmid (Myf41) was deter-
mined in extracts from 10TI/2 cells which were cotransfected with
vectors expressing the indicated myogenic determination factors.
quence element which most closely resembles the consensus
motif for MyoDI binding in the MCK enhancer is located
between nucleotides -14 and -7, downstream of the TATA
box and proximal to the transcriptional start site .
The Myf4 Promoter Directs Expression in Pbstmitotic
Myocytes butNot in ProliferatingMyoblasts
It has been reported previously that synthesis of myogenin
in muscle cell lines starts shortly afterFCS has been reduced
or replaced by HS, conditions which are generally applied
to induce differentiation and myotube formation (Wright et
al ., 1989 ; Braun et al ., 1989b ; Edmondson and Olson,
1989) . To investigate whether the isolated Myf4 promoter
contains the control regions which are sufficient to confer
muscle-specific and regulated expression, we have con-
structed reporter plasmids containing the sequence from
-1,124 to -10 (Myf4s), -1,124 to +54 (Myf41), and suc-
cessively shorter 5' deletions of the promoter fragment con-
taining the regions -883 to +54 (Myf4/883), -619 to +54
(Myf4/619), -377 to +54 (Myf4/377), and -211 to +54
(Myf4/211) . These 5' upstream sequences werejoined to the
CAT gene . The promoter fragment in Myf4s is truncated at
the 3' end and lacks the most proximal consensus element for
MyoD1 binding. As shown in Fig. 2, both reporter plasmids
Myf4s and Myf41 when transiently transfected into C2C12
muscle cells markedly stimulateCAT expression in differen-
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tiated myotubes but show only marginal activity in undiffer-
entiated myoblasts. Myf41 is approximately threefold more
active than Myf4s, whichmay suggest that the most proximal
region of the promoter contributes to the activity as a posi-
tive cis-acting element . Alternatively, the lack of the 5'
leader sequence (+1-+54) in Myf4s may also be responsible
for reducedCAT expression . As expected, transfection of the
0-actin promoter construct used as a constitutively ex-
pressed positive control results in equal CAT activities in
differentiated and undifferentiated cells . Myf4-anti contain-
ing the promoter fragment in the opposite orientation fails
to support transcription . The myotube-specific activation of
the Myf41 construct was further confirmed in four indepen-
dently isolated C2C12 clones that carry the stably integrated
reporter plasmid . As shown in Fig . 2 B, four distinct C2C12
clones promote CAT activity only when the cells are
differentiated . The activation of the Myf4 CAT construct
FigureS . CAT activity ofthe stably integrated Myf41 gene in C2C12
cells in the presence of serum and purified growth factors. (A)
Myf41 containing C2C12 cells (clone 4) were cultured for 2.5 dun-
der the indicated conditions and specific CAT activity was deter-
mined by standard procedures . FCS was depleted by two consecu-
tive runs over a Heparin-Sepharose column . Suramin was added at
150 AM . (B) Four dishes with 2 x 10° cells/5-ml dish were cul-
tured in parallel in the presence ofHS alone or in the presence of
bFGF (15 ng/ml), TGF-R (5 ng/ml), andEGF (30 ng/ml) . The me-
dium was changed daily and specific CAT activity was determined
for each day (1-4 d) .
910Figure 6. Expression ofMyf4 (myogenin) mRNA in C2C12 cells
cultured in the presence ofbacterial toxins, cAMP, or forskolin . To-
tal cellular RNA (20 hg) from cells cultured in the presence of the
indicated compounds for2.5 d was analyzed on Northern blot using
a Myf4-specific hybridization probe (specific activity 1 x 107 cpm/
wg) and a GAPDH-specific probe (specific activity 1 x 108 cpm/
lug) as control . Films were exposed for 18 h .
precedes the upregulation ofstructural muscle marker genes
by several days as shown forMCK activity (Fig . 2 C) . Simi-
lar results were obtained for the accumulation of MCK
mRNA as well asmRNAs for other muscle markers like my-
osin light and heavy chains (data not shown) .
To delimit the sequences involved in cell type-specific
transcription of the Myf4 gene with a resolution >l . I kb, the
5' deletion constructs were transfected into chick primary
breast muscle cells, skin fibroblasts, and hepatocytes and as-
sayed for the accumulation of CAT enzyme . The primary
muscle cells were chosen because they allowed higher CAT
activities in transient transfections than the C2C12 cell line.
As shown in Fig . 3, all Myf4 promoter fragments ranging in
size from "1,100 to 200 by are active in skeletal muscle cells
but not in fibroblasts and hepatocytes (data not shown) . Vari-
able efficiencies of DNA transfection in different cell types
were corrected according to 0-galactosidase enzyme activi-
ties obtained from the cotransfected RSVOgal plasmid .
In summary, these results demonstrate that the Myf4 pro-
moter directs expression in muscle cells which closely mi-
micks the cell type-specific and temporal regulation of the
endogenous myogenin gene (Wright et al., 1989 ; Edmond-
son and Olson, 1990) . Approximately 200 nucleotides up-
stream of the transcriptional start site are sufficient to main-
tain this regulation .
TheMyf4Promoter Is Silent in
1077/2 FIbroblasts but Can Be Transactivated by
Muscle-specific Ranscription Factors
We and others have previously shown that myogenin mRNA
accumulates only in cells that are committed to the myogenic
lineage and contain at least one muscle-specific H-L-H pro-
tein (Braun et al ., 1989a ; Edmondson and Olson, 1989 ;
Wright et al ., 1989) . Here, we demonstrate that the Myf4
promoter can be transactivated in 10TI/2 fibroblasts, when
muscle-specific transcription factors such as MyoD or Myf5
are expressed . As illustrated in Fig . 4, the Myf4l plasmid is
completely inactive when transiently transfected into 10TI/2
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fibroblasts alone or together with the control expression vec-
tor pEMSV Cotransfection of plasmids expressing Myf3,
Myf5, orMyf6 leads to activation ofthe Myf4 promoter. Ex-
pression ofmyogenin (Myf4) stimulates transcription weakly
but significantly. Similar results are obtained using the acti-
vator plasmids over a tenfold range of different concentra-
tions (data not shown) . We conclude from these observations
that the muscle regulatory H-L-H proteins themselves or
downstream-acting factors that become activated constitute
a positive stimulus for Myf4 expression . The same results
were obtained with 5'promoter deletions, suggesting that the
required target elements to confer this control are contained
in the proximal promoter region ofMyf4 (data not shown) .
Serum Components, bFGF, ?UF-0, andEGFExert
Negative Control on theMyf4Promoter
The downregulation of the myogenin (Myf4) gene by serum
components and the purified growth factors bFGF TGF-S,
and EGF have been observed previously (Heino and Mas-
sagud, 1990 ; Brunetti and Goldfine, 1990) . Here, we inves-
tigate the response of the isolated Myf4 promoter in the
Myf4l-CAT reporter construct which was stably integrated
in C2C12 muscle cells . These cells were grown in the ab-
sence and presence ofgrowth factors for 2-3 d and then ana-
lyzed for CAT activity . As shown in Fig . 5 A, maximal CAT
activity accumulates in cells growing in 5% HS while 20%
FCS results in a considerable decrease. WhenFCS has been
depleted for mitogens which bind to heparin-sepharose, some
of this repression is released . The activation is counteracted
by the addition ofbFGF (10 ng/ml), which also represses the
activation of the Myf4 promoter in the presence ofHS . The
inhibition is concentration dependent and can be obliterated
at least in part by the addition of suramin, a drug that pre-
vents ligand binding to theFGF receptor (Coffey et al ., 1987) .
Suppression ofMyf4 promoter activity is also observed when
cells are grown in the presence ofTGF-a andEGF. As shown
in Fig . 5 B in a time course experiment performed over 4 d,
Myf4 promoter-driven CAT activity increases in cells differ-
entiating in 5% HS . In contrast, in the presence of peptide
growth factors CAT activity is severely inhibited, particu-
larly 2 to 3 d aftermedium shift . Inhibition is less pronounced
at day 4 .
Although cells were generally seeded at low density to
avoid precocious differentiation, we always observed this
spontaneous activation ofMyf4-CAT when cells had grown
for more than 3 d in culture and reached confluency . In sum-
mary, our results indicate that serum components in FCS and
peptide growth factors repress Myf4 promoter activity. This
negative control by mitogens is mediated via target elements
in theMyf4 promoter located within 1.1 kb ofthe 5' upstream
sequence .
Phrtussis-and Cholera Toxin-sensitive Signaling
PathwaysA ffectAccumulation ofMyf4 mRNA
As an attempt to investigate signal transduction pathways
which may be involved in the regulation of the Myf4 gene,
we have determined the effects of bacterial toxins known to
modulateG proteins . CT and PT catalyze the ADP ribosyla-
tion ofGs and Gi proteins which respectively stimulate or
inhibit the activity of adenylate-cyclase and probably that of
other cellular functions (for review see Ui, 1990 ; Fishman,u
Go ft
Figure 7 . Effects of bacterial toxins PT and CT on the expression of MyAl in stably transfected C2C12 cells . Cells (2 x 10°/5-ml dish)
were cultured for 2.5 d under conditions as indicated . Myf41 CAT activity was determined as described under Materials and Methods.
1990) . The toxin concentrations that we used did not affect
the viability of the cells as judged by their tight attachment
to the culture dish, their general morphological appearance,
and the exclusion of trypan blue. RNAs from C2C12 muscle
cells growing in the presence of PT, CT, or other agents
known to affect intracellular CAMP concentrations, were
analyzed on a Northern blot using a Myf4-specific hybrid-
ization probe and a probe for GAPDH to control the RNA
loading on the blot. As shown in Fig . 6, in cells cultured in
HS or in FCS plus PT for 2 .5 d, Myf4 mRNA accumulates
to readily detectable levels. In cells cultured inFCS or inHS
plus db-cAMP, CT or forskolin accumulation of Myf4
mRNA is severely diminished . This result indicates that CT
suppresses Myf4 expression probably through increased
cAMP levels, whereas PT appears to stimulate Myf4 syn-
thesis .
To test whether the observed effects could be mediated via
the l .l.-kb promoter fragment of the Myf4 gene, the same
experiments were performed with C2C12 cells containing
the Myf41-CAT reporter gene . As shown in Fig . 7, the basal
promoter activity of the Myf41 plasmid in cells growing in
20% FCS (Fig . 7 A) and the elevated Myf4 promoter activity
in cells cultured in HS (Fig . 7 C) are inhibited by CT in a
concentration-dependent fashion . In contrast, PT strongly
stimulates the Myf4 promoter from basal activity to a level
that approaches that in differentiating cells cultured in the
presence of HS (Fig . 7 A) . PT plus HS elevates Myf4 pro-
moter activity two- to threefold above the level obtained in
HS alone (Fig. 7 B) . The stimulatory effect by PT is almost
completely abolished by basic FGF or TGF-a when added
in concentrations that prevent cellular differentiation (Fig . 7
B) . The simultaneous administration of CT and PT results
in an intermediate Myf4 activity level which confirms their
antagonistic effects (Fig. 7 C) . Taken together, the results
show that the stimulation of the Myf4 promoter by PT ap-
pears to be independent ofthe serum conditions, since both
the basal level in FCS and the elevated level in HS can be
further increased which argues for a positive transcription
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signal and not for just the counteraction of the negative
effects by serum components . Interestingly, PT fails to abol-
ish the repression of the Myf4 promoter exerted by the pep-
tide growth factors bFGF and TGF-/3 . To test whether the
stimulation ofMyf4 gene activity byPTmay involve changes
in CAMP levels, we have analyzed the intracellular concen-
tration ofcAMP. In contrast to CT which leads to elevation
of cAMP, PT does not noticeably alter CAMP levels in
C2C12 cells (data not shown) . We therefore conclude thatPT
activates the Myf4 promoter by a pathway that antagonizes
the effect of high concentrations ofcAMP but most likely is
not mediated via cAMP
It has been demonstrated previously that treating cells
withCT increases intracellular levels ofcAMP (Gill, 1977) .
Consequently, if inhibition of Myf4 expression by CT in-
volves cAMP, othercompounds that lead to elevatedcAMP
levels should also reduce the activity of Myf41-CAT. As
shown in Fig . 8 A, C2C12 myoblasts cultured in HS in the
presence ofCT (2.5 pg/ml), forskolin (34 ,UM) ordb-cAMP
(3 mM) exhibit reduced CAT activities, particularly during
the early phase of the 4-d culturing period . The repression
becomes less pronounced at later stageswhen the cells reach
confluency. In C2C12 cell lines carrying stably transfected
a-actin CAT or RSVCAT plasmids, treatment with CT, for-
skolin, db-cAMP, and PT has no effect on CAT activities,
which formally shows that these agents do not alter the sta-
bility or activity ofCATmRNA or protein (Fig . 8B) . Taken
together, these results suggest that elevated levels ofcAMP
reduceMyf4 promoter activity, particularly in cells that have
not yet initiated morphological differentiation . At later
stages, a compensatory mechanismmay counteract the nega-
tive control exerted by cAMP .
The Response oftheMyf4 Promoter Isan
Early EventandDoes NotDependon Morphological
Di fferentiation ofMuscle Cells
To examine the activation of the Myf4 promoter in single
myocytes under the influence ofvarious extrinsic factors, weproduced a stable C2C12 muscle cell line that carries the
Myf4-nls LacZ reporter plasmid . This construct contains
the lacZ gene modified with a nuclear localization signal
(Bonnerot et al ., 1987) under the control ofthe human Myf4
gene promoter. Nuclear staining for 0-galactosidase activity
is expected to be seen in differentiating but not in proliferat-
ing muscle cells . Indeed, in C2C12 cells growing in the pres-
ence of20% FCS, little or no R-galactosidase staining is ob-
served (data not shown), whereas in C2C12 cells growing in
the presence of 5% HS, numerous nuclei appear stained
(Fig . 9, A and B) . As shown for cells 2-3 d after the shift
to differentiation medium (Fig . 9 B), the Myf4 promoter is
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Figure 8. (A) Inhibition of
theMyAl promoter in C2C12
cells in the presence of CT
(2 .5 Ag/ml), forskolin (34 AM),
and dibutyryl-cAMP (3mM) .
Specific CAT activity was de-
termined over 4 d . Mediawere
changed daily. (B) Bacterial
toxins and cAMP have no
effect on the constitutively ex-
pressed 0-actin-CAT andRSV
CAT reporter plasmids in sta-
bly transfected C2C12 cell
lines . These control experi-
ments were performed as de-
scribed above and under Ma-
terials and Methods.
activated in the majority of mononucleated cells before any
morphological alterations . Interestingly, there is significant
variability among the cells in numbers and intensity of
stained nuclei, both in mononucleated myoblasts and in mul-
tinucleated myotubes . Even after culturing cells in HS for
5 d some myocytes do not express a-galactosidase (Fig . 9
A) . This variation within the cell population has been seen
in the parental clone as well as in several serial subclones,
which excludes the possibility of a heterogeneous cell popu-
lation . Similar variability of gene expression among muscle
cells in culture has been observed previously for the accumu-
lation of MyoD in differentiated C2C12 muscle cells (Tap-
913Figure 9 . Myf4 promoter activity in C2C12 cells stably transfected with the Myf4-nls lacZ gene . Gene activation is indicated by the nuclear
a-galactosidase activity visualized by cytochemical staining. Cells were cultured inHS for5 d(A) or 3d(B) and in the presence ofb-FGF
(15 ng/ml) (C), TGF-(3 (5 ng/ml) (D), cholera toxin (2.5 jg/ml) (E), and pertussis toxin (50 ng/ml) (F) . Bar, 45 tm .
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914scoff et al., 1988) . In C2C12 cells treated with bFGF (Fig.
9 C), TGF0 (Fig. 9 D), or CT (Fig. 9 E) general suppression
of the Myf4 promoter occurs even in the presence of HS
confirmingour previous results obtained with the Myf4-CAT
reporter construct. The negative control exerted by these
agents appears to be more homogenous since almost all
cells lose the LacZ staining. In contrast, treatment with PT
strongly stimulates the Myf4 promoter as seen by the very
intense staining of most nuclei, exceeding that in control
myoblasts grown in the presence of HS alone (Fig. 9 B). Al-
though PT activates the Myf4 promoter, it does not lead to
fusion of myoblasts, indicating once more that transcrip-
tional activation of the Myf4 gene is an early event during
the differentiation process. The experiment shows further-
more that cell proliferation and the regulation of the Myf4
promoter are uncoupled since CT which inhibits the Myf4
promoter and PT which stimulates Myf4 transcription, both
inhibit proliferation (Kelvin et al ., 1990 a,b) .
Discussion
The identification of a family of muscle regulatory genes
provides a genetic framework in which molecular mecha-
nisms involved in the development of skeletal muscle cells
can be studied. While it is evident that the capacity of the
myogenic factors to bind to DNA (Buskin and Hauschka,
1989; Lassar et al., 1989a ; Braun et al., 1990), to interact
with other regulatory proteins (Benezra et al ., 1990; Bren-
nan and Olson, 1990; Braun et al ., 1990; Murre et al.,
1990a,b; Davis et al . 1990), and to transactivate muscle
promoters (Braun et al., 1990a,b; Rosenthal et al., 1990)
may all constitute important levels of control, the most basic
regulation of myogenesis concerns the expression of the
muscle determination genes themselves.
Besides the fact that Myf genes are only expressed in
skeletal muscle cells, little is known about their regulation.
Among the MyoD gene family, Myf4 (myogenin) seems par-
ticularly interesting since it is the only gene that is expressed
in every known muscle cell line and therefore may be the
most critical factor for the maintenance ofthe differentiated
phenotype. This idea is further supported by the observation
that Myf4 expression is strictly initiated at the onset oftermi-
nal differentiation, unlike the other myogenic factors which
are already expressed in determined myoblasts before dif-
ferentiation. Furthermore, Brunetti and Goldfine (1990)
have shown that repression of myogenin synthesis by an-
tisense oligonucleotides results in down-regulation of the
muscle-type acetylcholine receptor in BC3H1 cells, suggest-
ing that myogenin is crucial for at least some aspects of ter-
minal differentiation.
To begin to investigate signals and mechanisms that are
important for the regulation of the myogenin gene, we have
isolated and sequenced the human Myf4 gene and its pro-
moter. The gene is organized in three exons, very similar to
the mouse herculin (Miner and Wold, 1990) and the human
and mouse Myf5 genes (our unpublished results), suggesting
a common ancestor although their nucleotide sequences out-
side of the highly conserved helix-loop-helix domain have
considerably diverged . The construction of reporter plas-
mids which are controlled by the Myf4 promoter allows the
analysis of the cellular requirements for its activation. As our
results demonstrate, a 1.1-kb promoter fragment allows
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efficient and regulated activity in C2C12 muscle cells and
-200 nucleotides are sufficient to confer cell type-specific
expression in chicken primary breast muscle cultures. In
contrast, nonmuscle cells like C3H mouse IOTl/2 fibro-
blasts, or chicken primary skin fibroblasts and hepatocytes
do not support transcription of the Myf4 promoter, which
suggests that these cells either contain negative control fac-
tors or that they miss crucial positive transcription factors,
or both. The failure to express the Myf4 promoter in 1071/2
fibroblasts could be caused by the absence of positive tran-
scription factors since constitutive expression ofthe muscle-
specific H-L-H proteins Myf3 (MyoDl), Myf5 and Myf6,
results in marked stimulation of the Myf4 promoter. This re-
sult provides confirmation for the earlier observations that
the forced expression ofMyoD or Myf5 in 1071/2 fibroblasts
leads to the activation of the endogenous myogenin gene
(Thayer et al ., 1989; Braun et al., 1989b). A survey of the
Myf4 promoter sequence used in our transactivation experi-
ments indicates the existence of several consensus motifs
(E-boxes) which resemble the MyoD binding site, previously
identified in the muscle-specific enhancer of the MCK gene
(Buskin and Hauschka, 1989) and in other muscle-specific
genes (Yutzey et al., 1990; Rosenthal et al., 1990). Although
we have not investigated the functional significance of these
sequence elements in detail, it is reasonable to assume that
at least some of them are involved in Myf4 promoter regula-
tion as they have been conserved in evolution from mouse
to man (E. Olson, personal communication) . Further studies
will be performed to dissect the functional sites for protein
interactions which may be required for the activation of the
Myf4 promoter.
In skeletal muscle cells a general antagonism between
proliferation and the acquisition of the differentiated pheno-
type exists. Consequently, when muscle cells differentiate,
they irreversibly withdraw from the cell cycle before they
start to synthesize muscle-specific proteins. It has been
demonstrated for several muscle cell lines that serum com-
ponents and the addition ofthe growth factors bFGF, TGF-,Q,
or EGF will prevent differentiation and shut down expression
of muscle marker genes like MCK and actin (Spizz: et al.,
1986; Clegg et al., 1987; Olson et al., 1986; Florini and Ew-
ton, 1988; Lathrop et al., 1985; Wice et al., 1987; Munson
et al ., 1982; Wang and Rubenstein, 1988) . More recently,
it was shown for the BC3H1 muscle cell line that prolifera-
tion and differentiation may be regulated by cAMP-depen-
dent and cAMPRindependent pathways (Hu and Olson,
1988), as well as by signal transduction cascades which in-
volve G proteins (Kelvin et al., 1989a,b) . We have addressed
the question of how these signals will affect the activity of
the Myf4 gene, as one of the crucial muscle determining fac-
tors. As we demonstrate here, the Myf4 gene and its isolated
promoter in C2C12 cells are subject to negative control by
serum mitogens and peptide growth factors. The DNA target
elements for this effect are located within 1.1 kb of the 5' up-
stream sequence. This result confirms and extends the obser-
vations on the endogenous myogenin genes in BC3H1 cells
and L6E9 cells which are also repressed by serum, bFGF,
and TGF0 (Brunetti and Goldfine, 1989; Heino and Mas-
sagud, 1990. Similar repression has also been shown for the
MyoD gene (Vaidya et al ., 1989) . It is presently unclear
whether the inhibition exerted by FCS, bFGF, TGFO, and
EGF involves identical target sequences on the Myf4 pro-
91 5moter and whether the same or overlapping signaling path-
ways are part of this control .
For some ofthe growth factor receptors it has been shown
that they contain an intracellular tyrosine kinase domain
(Westermark and Heldin, 1989 ; Yarden and Ullrich, 1988).
The cellular substrates and phosphorylation events, which
probably involve a number of protein kinases including
CAMP-dependent protein kinase A and protein kinase C, and
the potential signaling cascades between membrane recep-
tors and the nucleus (Edelmann et al., 1987; Kikkawa et al.,
1989) have not been elucidated. In preliminary experiments
involving compounds that modulate protein kinase C activ-
ity, we have obtained no major effects on Myf4 promoter ac-
tivity (data not shown). Employing reagents known to modu-
late cAMP-dependent events, we demonstrate here that
elevation of intracellular cAMP levels by forskolin, CT, or
dibutyryl CAMP severely represses expression of the endog-
enous Myf4 gene and its isolated promoter similar to the ac-
tion of serum mitogens and growth factors. It is unlikely,
however, that the mitogens act via cAMP since our results
(data not shown), as well as those reported by others (Hu and
Olson, 1988; Kelvin et al., 1989x), show that growth factors
do not significantly increase intracellular cAMP concentra-
tions. We therefore conclude that repression ofthe Myf4 pro-
moter can be conveyed by cAMP-dependent and cAMP-
independent mechanisms. The possible involvement of pro-
tein kinase A in the event of negative regulation is under in-
vestigation.
Myogenin and MyoD are known to be phosphorylated
proteins (Brennan and Olson, 1990; Tapscott et al., 1988) .
It is tempting to speculate that the way through which CAMP
may suppress Myf4 expression involves changes in the phos-
phorylation of MyoD, thereby modulating the activity of
MyoD as a positive transcription factor of the Myf4 pro-
moter. Alternatively, cAMP may exert its negative control
through the proto-oncogene product c-fos. It has been
reported that elevated expression of fos protein inhibits tran-
scription ofthe MyoD1 and myogenin genes andprevents ter-
minal differentiation of myoblasts (Lassar et al ., 19896;
Rahm and Sejersen, 1989). Increase in intracellular levels of
cAMP stimulates the transcription ofthe immediate early re-
sponse gene c-fos. Sassone-Corsi et al. (1988) have shown
that the c-fos promoter contains a cAMP response element
(CRE) that mediates regulation by the CRE binding protein.
Transcription of the c-fos gene is also stimulated by serum
(Treisman, 1986), EGF (Prywes and Roeder, 1986), and
FGF (Sheng et al., 1988). Thus, both the effect of growth
factors and CAMP on the activity of the Myf4 promoter
could be mediated by c-fos.
Administration of PT to C2C12 muscle cells activates the
Myf4 gene in a dose-dependent fashion both in the presence
of FCS (serum mitogens) and HS. G proteins, a family of
membrane-associated GTP binding proteins, are believed to
transduce stimulatory and inhibitory signals from receptors
to intracellular effector molecules (for review see Gilman,
1984, 1987; Lefkowitz and Caron, 1988). As muscle differ-
entiation is regulated by multiple growth factors, G proteins
are obvious candidates to be involved in signal transduction.
Kelvin et al. (1989x) have recently shown that PT, a specific
probe for inhibitory G proteins (Ui, 1990), inhibits prolifer-
ation and stimulates differentiation of BC3H1 cells. They
furthermore demonstrated that the PT-sensitive pathway
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affects signals from the thrombin receptor, but not from FGF
and EGF receptors or inhibitory signals exerted by the Har-
vey ras G protein homologue (Kelvin et al., 19896). These
observations indicate that muscle cell differentiation can be
regulated by PTsensitive and PTinsensitive pathways. In
agreement with these findings, we observe strong stimula-
tion of the Myf4 promoter by PT in FCS and HS, but only
weak activation in the presence ofbFGF and TGF-0, suggest-
ing that components present in FCS prevent Myf4 expression
through a mechanism that is different from that exerted by
bFGF and TGF-0. Moreover, we believe that PT should
affect a pathway that operates in FCS and HS since the Myf4
promoter is activated in both media. As multiple intracellu-
lar effectors are regulated via pertussis toxin substrate Gpro-
teins, for example, cation channels and processes of calcium
homeostasis (for review see Ui 1990), further studies will
be required to elucidate the mechanisms involved in PT
sensitive activation of Myf4 gene expression.
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